Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine

Vaccine

Volumn 27, Issue 3, 2009, Pages 446-453

  Gillet, Y ^a   Steri, G C ^b   Behre, U ^c   Arsene J P ^d   Lanse, X ^d   Helm, K ^e   Esposito, S ^f   Meister, N ^g   Desole, M G ^h   Douha, M ⁱ   Willems, P ⁱ  

^a HOSPICES CIVILS DE LYON   (France)

^b Territorial Department of Nephrology and Dialysis   (Italy)

^c Pediatric Office   (Germany)

^d Pediatric Office   (France)

^e Pediatric Office   (Germany)

^f UNIVERSITY OF MILAN   (Italy)

^g Pediatric Office   (Germany)

^h Neurology Unit   (Italy)

ⁱ GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Immunogenicity; Measles mumps rubella varicella vaccine; Safety

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; PRIORIX TETRA; RUBELLA ANTIBODY; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE;

ANTIBODY TITER; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; NORMAL HUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECTUM TEMPERATURE; SCHOOL CHILD; SEROCONVERSION; SINGLE DRUG DOSE; SYMPTOM; TREATMENT RESPONSE;

ANTIBODIES, VIRAL; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE;

EID: 57749173149     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.10.064     Document Type: Article

References (29)

1. World Health Organization. Measles vaccines. Wkly Epidemiol Rec 79 (2004) 130-142
2. Empfehlungen des Obersten Sanitätsrates; 2008. Impfplan Österreich 2008: Available at: http://www.bmgfj.gv.at/cms/site/attachments/1/4/0/CH0780/CMS103891301041 2/b)_impfplan_20081.pdf [Accessed September 15, 2008].
3. World Health Organization. WHO vaccine preventable disease monitoring system: immunization schedules by antigen, selection centre; 2008. Available at: http://www.who.int/immunization_monitoring/en/globalsummary/schedulesele ct.cfm [Accessed September 15, 2008].
4. Institut de Veille Sanitaire. Calendrier vaccinal 2005 et autres avis du conseil supérieur d'hygiène publique de France relatifs à la vaccination. Bulletin épidémiologique hebdomadaire 29-30 (2005) 142
5. Robert Koch Institute. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: July 2006. Epidemiol Bull 30 (2006) 235-254
6. Bundesamt für Gesundheit. Impfplan für routinemässige Schutzimpfungen. Stand August 2001. Ordner "Infektionskrank-heiten-Diagnose und Bekämpfung" Supplementum VIII: 1-6 (2001), BAG, Bern
7. Heininger U., and Seward J.F. Varicella. Lancet 368 (2006) 1365-1376
8. Marin M., Güris D., Chaves S.S., Schmid S., Seward J.F., Advisory Committee on Immunization Practices, and Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 June (RR-4) (2007) 1-40
9. Vesikari T., Sadzot-Delvaux C., Rentier B., and Gershon A. Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe. A role for the combined vaccine. Pediatr Infect Dis J 26 (2007) 632-638
10. Rawson H., Crampin A., and Noah N. Deaths from chickenpox in England and Wales 1995-7: analysis of routine mortality data. BMJ 323 (2001) 1091-1093
11. Boelle P.Y., and Hanslik T. Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol Infect 129 (2002) 599-606
12. Banz K., Wagenpfeil S., Neiss A., Hammerschmidt T., and Wutzler P. The burden of varicella in Germany: potential risks and economic impact. Eur J Health Econ 5 (2004) 46-53
13. Gil A., San-Martín M., Carrasco P., and González A. Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine 22 (2004) 3947-3951
14. Bonhoeffer J., Baer G., and Muechleisen B. Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents. Eur J Pediatr 164 (2005) 366-370
15. Cameron J.C., Allan G., Johnston F., Finn A., Heath P.T., and Booy R. Severe complications of chickenpox in hospitalised children in the UK and Ireland. Arch Dis Child 92 (2007) 1062-1066
16. Galil K., Lee B., Strine T., Carraher C., Baughman A.L., Eaton M., et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med 347 (2002) 1909-1915
17. Gershon A.A. Varicella vaccine-are two doses better than one?. N Engl J Med 347 (2002) 1962-1963
18. Arvin A., and Gershon A. Control of varicella. Why is a two-dose schedule necessary?. Pediatr Infect Dis J 25 (2006) 475-476
19. Lopez A.S., Guris D., Zimmerman L., Gladden L., Moore T., Haselow D.T., et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?. Pediatrics 117 (2006) e1070-e1077
20. Chaves S.S., Gargiullo P., Zhang J.X., Civen R., Guris D., Mascola L., et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med 356 (2007) 1121-1129
21. Goh P., Lim F.S., Han H.H., and Willems P. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Infection 35 (2007) 326-333
22. Knuf M., Habermehl P., Zepp F., Mannhardt-Laakmann W., Howe B., and Friedland L.R. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J 25 (2006) 12-18
23. Vesikari T., Baer M., and Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Pediatr Infect Dis J 26 (2007) 153-158
24. Schuster V., Otto W., Maurer L., Tcherepnine P., Pfletschinger U., Kindler K., et al. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J 27 8 (2008) 724-730
25. Pebody R.G., Gay N.J., Hesketh L.M., Vyse A., Morgan-Capner P., Brown D.W., et al. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. Vaccine 20 (2002) 1134-1140
26. Wellington K., and Goa K.L. Measles, mumps, rubella vaccine (Priorix™; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella. Drugs 63 (2003) 2107-2126
27. ®). Hum Vaccine 2 (2006) 205-214
28. Watson B., Boardman C., Laufer D., Piercy S., Tustin N., Olaleye D., et al. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis 20 (1995) 316-319
29. Kuter B., Matthews H., Shinefield H., Black S., Dennehy P., Watson B., et al., Study Group for Varilvax. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 23 (2004) 132-137